- Home
- KOS vs ANAB Comparison
KOS vs ANAB Comparison
Compare KOS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOS | ANAB |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2011 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KOS | ANAB |
|---|---|---|
| Price | $2.98 | $54.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $1.91 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 10.7M | 403.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,288,352,000.00 | $234,603,000.00 |
| Revenue This Year | $27.11 | N/A |
| Revenue Next Year | N/A | $52.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $0.84 | $17.11 |
| 52 Week High | $3.34 | $73.30 |
Technical Indicators
Market Signals| Indicator | KOS | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.97 | 43.30 |
| Support Level | $2.65 | $53.46 |
| Resistance Level | $3.09 | $57.70 |
| Average True Range (ATR) | 0.13 | 2.42 |
| MACD | -0.00 | -0.21 |
| Stochastic Oscillator | 77.66 | 13.88 |
Price Performance
Historical ComparisonAbout KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).